case_images: PMC10965285_01
case_images: Skin involvement at Sucukinumab therapy withdrawal.
case_images: CRII2024-9076852.001.jpg
case_images: PMC10965285_01_CRII2024-9076852.001.jpg
case_images: fig1
case_images: A skin biopsy was performed on one of the new lesions, and it confirmed the clinical suspicion of drug-induced dermatitis, resulting in a diagnosis of erythema multiforme (Figure 1).
case_images: Disease activity indexes during Risankizumab therapy, measured in weeks after therapy initiation. DAPSA, disease activity in psoriatic arthritis; PtGA, patient global assessment; PASI, psoriasis area and severity index; and BSA, body surface area.
case_images: CRII2024-9076852.002.jpg
case_images: PMC10965285_01_CRII2024-9076852.002.jpg
case_images: fig2
case_images: The last evaluation was performed at 52 weeks, the patient was still in clinical remission (DAPSA = 5, PtGA = 12, PASI = 0, and BSA = 1).  Figure 2 pictures clinical indexes during follow-up.